Amyotrophic Lateral Sclerosis News and Research

RSS

UCSF professor receives National Medal of Science

UCSF Nobel laureate Stanley B. Prusiner, MD, UCSF professor of neurology and director of the Institute for Neurodegenerative Diseases, today (Oct. 15, 2010) was named to receive the National Medal of Science, the nation's highest honor for science and technology.

18 Oct 2010

Knopp Neurosciences forms new parent entity

Knopp Neurosciences Inc. announced today that it has formed a new parent entity called Knopp Biosciences LLC to expand operations with the goal of becoming a more broadly integrated biopharmaceutical company.

15 Oct 2010

'Brain-computer interface' development receives Arizona Biomedical Research Commission grant

Efforts to advance technology to aid people who have lost communication and movement abilities are getting support from an Arizona Biomedical Research Commission grant for a project combining resources and expertise at Arizona State University and the Children's Neuroscience Institute at Phoenix Children's Hospital.

14 Oct 2010

MOH approves BrainStorm's NurOwn stem cell therapy for Phase I/II clinical trial

BrainStorm Cell Therapeutics Inc. a leading developer of adult stem cell technologies and therapeutics, today announced that the Israeli Ministry of Health (MOH) has granted clearance for a Phase I/II clinical trial using the company's autologous NurOwn stem cell therapy in patients with amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's Disease.

11 Oct 2010

FDA designates NeuRx Diaphragm Pacing System as HUD device for ALS patients

Synapse Biomedical Inc. announces today that they have received the U.S. Food and Drug Administration (FDA) designation of the NeuRx Diaphragm Pacing System (DPS) as a Humanitarian Use Device (HUD) for amyotrophic lateral sclerosis (ALS) patients with a stimulatable diaphragm who are experiencing chronic hypoventilation and has now submitted for Humanitarian Device Exemption (HDE) approval.

11 Oct 2010

Neuraltus achieves last patient out for NP001, NP002 studies

Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases, announced today the Company has achieved last patient out in two studies: a Phase 1 clinical study of NP001 in patients with Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease) and a Phase 1/2 clinical study of NP002 in patients with L-dopa-induced dyskinesias (muscle movement disorders).

5 Oct 2010

CVS/pharmacy's fundraising campaign raises $4.1 million for ALS research

In just 21 days, CVS/pharmacy's ninth annual in-store fundraising campaign to support the fight against amyotrophic lateral sclerosis (ALS) brought in $4.1 million. The funds raised by the campaign will be donated to the Boston-based ALS Therapy Alliance (ATA) to support the funding of new clinical research aimed at developing new therapies for ALS patients and focused on the ultimate goal of finding a cure for ALS.

1 Oct 2010

USFDA approves Sun Pharmaceutical's ANDA to market Rilutek tablets

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted a tentative approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Sanofi Aventis's Rilutek® tablets 50 mg.

29 Sep 2010

AVANIR's AVP-923 Phase III STAR trial results published in 'Annals of Neurology' website

AVANIR Pharmaceuticals, Inc. today announced the electronic publication of the results of the pivotal Phase III STAR trial of its investigational drug AVP-923 (dextromethorphan/quinidine) in the Annals of Neurology. The publication entitled "Dextromethorphan Plus Ultra-Low-Dose Quinidine Reduces Pseudobulbar Affect" evaluated two low dose formulations compared to placebo in the treatment of pseudobulbar affect (PBA) in patients with underlying amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS).

15 Sep 2010

Metabolon receives patent for metabolic age analysis

Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announced today the grant of US Patent 7,781,160 entitled "Biomarkers Related to Metabolic Age and Methods Using the Same". The USPTO awarded the patent to Metabolon on August 24, 2010. This is the 12th patent issued to Metabolon.

14 Sep 2010

Special journal issue highlights obsessive compulsive disorder and Tourette's disorder therapies

Pediatric onset obsessive compulsive disorder (OCD) and Tourette's disorder (TD) share similarities in their underlying genetic and environmental factors, psychiatric features, and treatment methods. Advances in understanding the neurobiological basis of these disorders and discovering new and more effective therapies are highlighted in a special issue on OCD and TD in Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal published by Mary Ann Liebert, Inc.

10 Sep 2010

Research on motor neuron subtype may provide useful therapy for neuron diseases

Scientists have devised a method for coaxing mouse embryonic stem cells into forming a highly specific motor neuron subtype. The research, published by Cell Press in the September 3rd issue of the journal Cell Stem Cell, provides new insight into motor neuron differentiation and may prove useful for devising and testing future therapies for motor neuron diseases.

3 Sep 2010

Critical mechanistic link between mutant protein and disease pathogenesis in ALS uncovered

New research uncovers what may be a primary neuron-damaging insult that occurs in an inherited form of a devastating neurodegenerative disorder. The study, published by Cell Press in the August 26th issue of the journal Neuron, describes a critical mechanistic link between a mutant protein and disease pathogenesis in an animal model of amyotrophic lateral sclerosis (ALS).

26 Aug 2010

Neuralstem files IND with FDA for spinal cord stem cell Phase I clinical trial for chronic spinal cord injury

Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin a Phase I safety clinical trial for chronic spinal cord injury with its spinal cord stem cells. This multicenter Phase I safety trial will enroll a total of 16 long-term, or chronic, spinal cord injury patients, with an American Spinal Injury Association (ASIA) Grade A level of impairment, one-to-two years post-injury.

26 Aug 2010

Ataxin 2 gene mutation contributes to Lou Gehrig's disease: Research

An international study led by biologists and neuroscientists from the University of Pennsylvania has identified a new genetic risk factor for amyotrophic lateral sclerosis, commonly known as ALS or Lou Gehrig's disease.

26 Aug 2010

Study finds genetic change in chromosome 4 causes FSHD

The Muscular Dystrophy Association today heralds a landmark muscular dystrophy advance by an international study team of scientists and physicians from the Netherlands, United States, France and Spain. Led by MDA-grantee Silvère van der Maarel, Ph.D., at Leiden University Medical Center in the Netherlands, the collaborative study of more than 2,300 people found that two distinct genetic changes on chromosome 4 must be present to cause facioscapulohumeral muscular dystrophy (FSHD).

21 Aug 2010

First pathological evidence of link between repeated head injuries and chronic traumatic Encephalomyopathy

Researchers with the Department of Veterans Affairs (VA) and the Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine have provided the first pathological evidence of a link between repeated head injuries—such as those experienced by athletes in contact sports such as boxing, football, and hockey—and a disease (chronic traumatic Encephalomyopathy) that resembles amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease.

20 Aug 2010

Muscular Dystrophy Association awards $14.1M in new grants

The Muscular Dystrophy Association, which has invested almost $39 million in 2010 in worldwide research seeking treatments and cures for muscle diseases, today announced that it has awarded $14.1 million in new grants.

20 Aug 2010

Biogen Idec, Knopp Neurosciences enter license agreement for KNS-760704 ALS drug candidate

Biogen Idec and Knopp Neurosciences today announced they have entered into an exclusive, worldwide license agreement under which Biogen Idec will develop and commercialize KNS-760704 (dexpramipexole) for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, and potentially other indications.

18 Aug 2010

MDA awards $14.1 million in new grants to advance treatments and cures for muscle diseases

18 Aug 2010

Amyotrophic Lateral Sclerosis News and Research

UCSF professor receives National Medal of Science

Knopp Neurosciences forms new parent entity

'Brain-computer interface' development receives Arizona Biomedical Research Commission grant

MOH approves BrainStorm's NurOwn stem cell therapy for Phase I/II clinical trial

FDA designates NeuRx Diaphragm Pacing System as HUD device for ALS patients

Neuraltus achieves last patient out for NP001, NP002 studies

CVS/pharmacy's fundraising campaign raises $4.1 million for ALS research

USFDA approves Sun Pharmaceutical's ANDA to market Rilutek tablets

AVANIR's AVP-923 Phase III STAR trial results published in 'Annals of Neurology' website

Metabolon receives patent for metabolic age analysis

Special journal issue highlights obsessive compulsive disorder and Tourette's disorder therapies

Research on motor neuron subtype may provide useful therapy for neuron diseases

Critical mechanistic link between mutant protein and disease pathogenesis in ALS uncovered

Neuralstem files IND with FDA for spinal cord stem cell Phase I clinical trial for chronic spinal cord injury

Ataxin 2 gene mutation contributes to Lou Gehrig's disease: Research

Study finds genetic change in chromosome 4 causes FSHD

First pathological evidence of link between repeated head injuries and chronic traumatic Encephalomyopathy

Muscular Dystrophy Association awards $14.1M in new grants

Biogen Idec, Knopp Neurosciences enter license agreement for KNS-760704 ALS drug candidate

MDA awards $14.1 million in new grants to advance treatments and cures for muscle diseases

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News